Project Grant HT94252410454
- The University of British Columbia (UBC) received a $507,035 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420). The grant, awarded on September 1, 2023, will fund research for "The Ovarian Cancer Observatory: Prevention, Impact, and Learning from Opportunistic Salpingectomy" over a 4-year period through August 31, 2027. As the prime grantee, UBC will leverage its expertise in medical research and data analysis...
- The University of British Columbia (UBC), through its Research Services division, has been awarded a $407,599 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 2-year research project titled "Epigenetic and Metabolomics Vulnerabilities in ASCL1-Driven NEPC Subtype" starting on September 1, 2024. This grant allows UBC researchers to leverage their expertise in biomedical research to...
- This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...
- The University of British Columbia (UBC) was awarded a $525,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) to engineer an effective combination therapy involving car T cells and regulatory T cells to control vascular composite allograft (VCA) rejection. The 3-year project, running from August 1, 2023 to July 31, 2026, will focus on developing innovative medical solutions to address transplant rejection issues for service...
- The University of British Columbia (UBC) was awarded a $561,584 project grant by the Defense Health Agency to conduct research on the measurement and impact of body composition using CT imaging in patients with germ cell tumors undergoing chemotherapy. This grant is funded under the Military Medical Research and Development Program (CFDA 12.420), which supports biomedical research to transform healthcare for service members and the public through innovative and impactful research, including...
- This Project Grant award of $1,477,615.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of British Columbia (UBC) to conduct comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer. The award period runs from April 15, 2025 through April 14, 2028. UBC, a prominent public research university in Canada, has significant...
- The University of British Columbia (UBC) received a $1,731,421.95 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) to provide advanced physiologic monitoring at the site of spinal cord injury. The 3-year project, with a start date of September 30, 2023, will focus on transforming healthcare for Service Members and the public through innovative and impactful research into medical solutions for the battlefield. As the...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $426,154.00 to The University of British Columbia (UBC) for the project "INVESTIGATING ASCL1-DRIVEN IMMUNOLOGICAL LANDSCAPES IN NEUROENDOCRINE PROSTATE CANCER: A STRATEGY FOR ENHANCING IMMUNOTHERAPY EFFICACY". The award period runs from September 1, 2025 to August 31, 2027. The project aims to investigate the role of the ASCL1 gene in shaping the tumor...
- The University of British Columbia was awarded a $2,498,328 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on using blood biomarkers to improve diagnosis of brain injury and assess dementia risk in survivors of intimate partner violence. The 4-year grant, awarded on June 1, 2024, will enable UBC researchers to leverage their expertise in biomedical research, clinical trials, and data analysis to...
- The University of British Columbia (UBC) was awarded a $5,738,391 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) with a start date of September 1, 2025 and an expected completion date of August 31, 2029. The grant will fund translational research to understand the pathophysiology of traumatic brain injury and nonfatal strangulation in the context of intimate partner violence. UBC, a prominent public research university in Canada,...
The U.S. Defense Health Agency awarded a $399,816 Project Grant to The University of British Columbia (UBC) for the project "ENGINEERING NEXT-GENERATION SELF-AMPLIFYING RNA THERAPEUTICS ENCODING BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES FOR TREATMENT OF OVARIAN CANCER." The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports UBC's research to develop innovative self-amplifying RNA-based therapies encoding bispecific T-cell engager antibodies for the treatment of ovarian cancer. As a prime contractor, UBC will leverage its world-class research facilities and expertise to advance this critical military medical research initiative over the 2-year performance period from August 2024 to July 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $399.8k | 6/5/24 |